AGC (5201) FY2026 Q1 Earnings Report

Quick View

Executive Summary

For Q1 of the fiscal year ending December 2026, AGC recorded increases in both revenue and profit, with particularly strong growth in operating income and net income significantly outpacing revenue growth, indicating qualitative improvement. Revenue was ¥5,379.6B (+7.7% YoY), operating income was ¥384.7B (+48.9%), profit before tax was ¥349.6B (+106.2%), and net income attributable to owners of the parent was ¥228.4B (+243.8%). The gross profit margin rose to 24.2% (from 23.3% in the same period of the previous year), while the SG&A ratio declined to 17.6%, improving the operating margin to 7.2% (from 5.2%, an improvement of +2.0pt). The main drivers were the return to profitability in Building Glass and increased profit in Chemicals.

Factors Affecting Business Performance

【Revenue】Revenue was ¥5,379.6B, up +7.7% YoY. Chemicals (¥1,568.7B, 29.2% of total, +9.7%) was the largest segment, followed by Automotive (¥1,375.8B, 25.6% of total, +6.9%) and Building Glass (¥1,118.1B, 20.8% of total, +8.5%). Electronics (¥897.9B, +4.1%) recorded relatively modest revenue growth, while Life Science (¥349.1B, +16.4%) posted the highest growth rate.

【Profit and Loss】Operating income was ¥384.7B (+48.9%), with the return of Building Glass from an operating loss of ¥9.3B in the same period of the previous year to operating income of ¥46.7B serving as the largest positive contributor. Chemicals also contributed to the increase in profit, with operating income of ¥152.2B (+37.3%), while Electronics recorded a decline in operating income to ¥122.6B (-12.6%), and Life Science continued to report an operating loss of ¥33.2B (a loss of ¥61.6B in the same period of the previous year). Profit before tax was ¥349.6B (+106.2%), aided not only by the increase in operating income but also by the expansion of equity-method investment gains and losses from ¥7.7B to ¥27.9B. Net income attributable to owners of the parent was ¥228.4B (+243.8%), maintaining strong growth even after deducting income taxes of ¥98.1B (an effective tax rate of approximately 28.1%). The company achieved growth in both revenue and profit, with improved margins in addition to higher revenue; notably, this improvement was accompanied by a qualitative transformation in the business structure.

Segment Analysis

Among the six segments, Chemicals was the largest profit contributor, with revenue of ¥1,568.7B (29.2% of total, +9.7%) and operating income of ¥152.2B (+37.3%, margin of 9.7%). Building Glass returned to profitability, with revenue of ¥1,118.1B (+8.5%) and operating income of ¥46.7B (an operating loss of ¥9.3B in the same period of the previous year), improving its margin to 4.2%. Automotive continued to deliver stable growth, with revenue of ¥1,375.8B (+6.9%) and operating income of ¥86.4B (+12.5%, margin of 6.3%). Electronics recorded a decline in operating income to ¥122.6B (-12.6%) against revenue of ¥897.9B (+4.1%); although its margin remained at the highest level among the segments at 13.7%, it was on a declining trend. Life Science achieved high growth in revenue of ¥349.1B (+16.4%) but continued to report an operating loss of ¥33.2B (a loss of ¥61.6B in the same period of the previous year), with a negative margin of 9.5%. Overall, the return to profitability in Building Glass and increased profit in Chemicals drove company-wide profit growth, while declining profitability in Electronics and continued losses in Life Science remain areas for improvement.

Key Financial Indicators

【Profitability】The operating margin was 7.2%, improving by 2.0pt from 5.2% in the same period of the previous year, driven by an increase in the gross profit margin to 24.2% (from 23.3%) and a decline in the SG&A ratio to 17.6% (from 18.3%). The net income margin attributable to owners of the parent rose to 4.2% (from 1.3%). 【Cash Quality】Operating cash flow (OCF) was ¥426.1B, approximately 1.7 times quarterly net income of ¥251.5B, indicating solid cash backing for earnings. 【Investment Efficiency】ROE based on quarterly results was 1.5%; however, when the quarterly figure is annualized, annualized ROE calculated using total asset turnover of approximately 0.72 times and financial leverage of approximately 1.74 times remains in the 6% range, indicating room to improve asset efficiency given the capital-intensive business structure. 【Financial Soundness】The equity ratio was 49.9% (largely unchanged from 50.3% at the end of the same period of the previous year), and the capital base remained stable, with total assets of ¥29,955.3B and net assets of ¥17,194.7B. Short-term interest-bearing debt increased by +37.0% from the end of the previous fiscal year to ¥1,349.8B, and the change in the funding structure warrants monitoring.

Cash Flow Analysis

Operating cash flow was ¥426.1B, down -5.3% YoY. Although positive cash flow was secured after deducting income tax payments of ¥134.9B and interest payments of ¥35.4B, working capital was pressured by increases in trade receivables of +¥182.7B and inventories of +¥60.7B, as well as a decrease in trade payables of -¥83.5B. Investing cash flow was -¥596.6B, with capital expenditures of -¥627.1B representing the largest expenditure item. As a result, free cash flow, combining operating and investing cash flow, was -¥170.6B, meaning that investment during the quarter exceeded internally generated cash. Financing cash flow was +¥397.4B; increased funding through short- and long-term interest-bearing debt offset dividend payments of -¥223.0B, and cash and cash equivalents increased by +¥251.8B from the end of the previous fiscal year to ¥1,198.5B. If capital expenditures continue to exceed operating cash flow, dependence on the funding structure may increase.

Quality of Earnings

The improvement in operating income of ¥384.7B was primarily attributable to recurring operating factors—namely, the return to profitability in Building Glass and increased profit in Chemicals—with limited impact from extraordinary or one-time factors. Other income of ¥33.4B and other expenses of ¥60.0B remained at approximately the same levels as in the same period of the previous year, while net financial income and expenses improved to -¥8.5B from -¥12.8B in the same period of the previous year, comprising financial income of ¥34.2B and financial expenses of ¥42.7B. The gap between profit before tax of ¥349.6B and net income attributable to owners of the parent of ¥228.4B was primarily attributable to income taxes of ¥98.1B and net income attributable to non-controlling interests of ¥23.1B, with no unusual adjustment items identified. Operating cash flow of ¥426.1B exceeded quarterly net income of ¥251.5B, indicating that accruals (the divergence between accrual and cash accounting) were limited and earnings quality was generally sound. However, increases in trade receivables and inventories remain factors weighing on earnings quality from a working-capital perspective. Comprehensive income was ¥350.1B (¥319.7B attributable to owners of the parent), exceeding net income of ¥228.4B, with positive contributions from foreign exchange factors—primarily foreign currency translation adjustments of +¥68.2B—boosting comprehensive income.

Earnings Forecasts and Guidance

The full-year company forecasts are revenue of ¥22,000B (YoY +6.9%), operating income of ¥1,500B (+17.7%), and net income of ¥900B (+11.3%), with no revisions to the earnings or dividend forecasts. Progress in Q1 was 24.5% for revenue and 25.6% for operating income, while progress for net income attributable to owners of the parent was 29.7% (¥228.4B in the current period against the full-year forecast of ¥770B), exceeding the standard progress rate of 25%. Operating income is generally tracking in line with the plan, while net income is ahead of schedule; recovery in Electronics’ profitability and reduction of Life Science’s losses will be key to achieving the full-year targets.

Shareholder Returns

The full-year dividend forecast is ¥210 per share, resulting in a payout ratio of approximately 57.8% against full-year forecast EPS of ¥363.12. Share repurchases were minimal at ¥0.04B during the quarter, leaving the total return ratio effectively at the same level as the payout ratio. Dividend payments during the quarter were ¥223.0B. Operating cash flow of ¥426.1B exceeded dividend payments, providing cash support; however, free cash flow including capital expenditures was negative at -¥170.6B, and dividend sustainability will depend on achievement of full-year earnings and working-capital trends.

Risk Factors

1. Elevated inventory levels: Inventories were ¥4,723.9B, accounting for 15.8% of total assets and increasing by +¥60.7B from the end of the previous fiscal year. On an annualized basis, inventory days were above 100 days, potentially resulting in valuation losses and increased working-capital requirements when demand fluctuates.

2. Declining profitability in the Electronics segment: Against revenue of ¥897.9B (+4.1%), operating income was ¥122.6B (-12.6%), and the margin declined from the same period of the previous year. Continued deterioration in the profitability of the group’s highest-margin business could constrain the pace of improvement in company-wide margins.

3. Continued losses in Life Science: Despite revenue growth of +16.4% to ¥349.1B, an operating loss of ¥33.2B (a loss of ¥61.6B in the same period of the previous year) continued. The segment has not yet achieved profitability through revenue growth alone, and progress in improving profitability remains a key focus.

Industry Benchmark (Reference; Compiled by the Company)

Profitability and Returns

Growth and Capital Efficiency

※Source: Compiled by the Company

Key Earnings Highlights

1. The operating margin improved by +2.0pt YoY to 7.2%, led by the return to profitability in Building Glass and increased profit in Chemicals. The sustainability of the improvement will depend on demand conditions in Building Glass and recovery in Electronics’ profitability.

2. Operating cash flow was approximately 1.7 times net income, indicating solid cash backing for earnings; however, increases in inventories and trade receivables pressured working capital, and free cash flow was -¥170.6B as operating cash flow was insufficient to cover capital expenditures of ¥627.1B. Inventory trends will be a key point to monitor when assessing future liquidity.

3. Progress against the full-year forecasts was generally on track, at 25.6% for operating income and 29.7% for net income attributable to owners of the parent. The pace of recovery in Electronics’ profitability and reduction of Life Science’s losses will be key to achieving the full-year plan.

Theoretical Share Price (Reference Value)

Sensitivity: ¥6,193–¥6,546 at cost of equity ±1%, and ¥6,343–¥6,380 at ω±0.1.

Notes:

• Net income is substantially compressed relative to operating income due to tax burden, acquisition-related expenses, non-controlling interests, and other factors (net income ÷ operating income 51%). This figure reflects that compression at face value; if the factors are temporary, underlying earnings power may be higher.
• As forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the end of the quarter are used (there is a timing difference from the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not forecast or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, consulting with a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

AGC delivered a strong FY2026 Q1 earnings recovery, with operating leverage and a turnaround in architectural glass more than offsetting mixed conditions across its portfolio. Revenue increased 7.7% YoY to ¥537.97bn. Operating income rose 48.9% to ¥38.47bn, materially outpacing sales growth. Operating margin expanded by 198bp YoY to 7.2% from 5.2%. Gross margin improved by 91bp to 24.2%, indicating that pricing, mix and/or manufacturing cost absorption improved. SG&A increased only 3.5% YoY to ¥94.72bn, below revenue growth, reducing the SG&A-to-sales ratio by approximately 70bp to 17.6%. Equity-method income increased to ¥2.79bn from ¥0.77bn, providing an additional contribution to operating income. Other income increased to ¥3.34bn while other expenses fell to ¥6.00bn, lifting business profit to ¥35.81bn from ¥18.23bn. Net income attributable to owners surged 243.8% YoY to ¥22.84bn, or ¥107.73 per share, benefiting both from the operating recovery and the comparatively weak prior-year base. The effective tax rate was 28.1%, and the tax burden in the five-factor DuPont analysis was 0.653x. Operating cash flow was ¥42.61bn, equivalent to 1.87x consolidated net income, demonstrating solid cash realization of reported earnings. However, operating cash flow was constrained by a ¥18.27bn receivables increase, a ¥6.07bn inventory increase and a ¥8.35bn payables decrease. Capital expenditure of ¥62.71bn exceeded operating cash flow, resulting in negative free cash flow of ¥17.06bn in the quarter. The cash shortfall was funded in part by net financing inflows, including higher short-term borrowings and net long-term debt issuance. Q1 achieved 24.5% of FY2026 sales guidance, 25.6% of operating-income guidance and 29.7% of parent-attributable profit guidance, broadly consistent with normal first-quarter progress and modestly ahead on profit. The full-year guidance remains unchanged, implying that management expects the Q1 margin recovery to remain broadly sustainable despite continued cyclicality in electronics, construction glass, automotive production and chemicals.

Profitability Analysis

Annualized DuPont ROE was 5.3%, decomposed into a 4.2% net profit margin, 0.718x annualized asset turnover and 1.74x financial leverage. The principal driver of the YoY earnings improvement was margin expansion rather than balance-sheet leverage: operating margin improved 198bp to 7.2%, while gross margin improved 91bp to 24.2%. Revenue growth of 7.7% exceeded SG&A growth of 3.5%, creating favorable operating leverage and reducing the SG&A ratio to 17.6% from 18.3%. The largest segment profit improvement came from Building Glass, which moved to a ¥4.68bn operating profit from a ¥0.93bn loss; its segment margin improved to 4.2% from negative 0.9%. Chemicals remained the core business by operating-income contribution, generating ¥15.22bn of segment operating income, or roughly 40% of aggregate segment profit, on ¥156.87bn of revenue; its margin expanded to 9.7% from 7.7%. Electronics remained the highest-margin major segment at 13.7%, but segment profit declined 12.6% YoY to ¥12.27bn despite revenue growth of 4.1%, compressing margin by roughly 250bp. Automotive revenue increased 6.9% to ¥137.58bn and operating income increased 12.5% to ¥8.64bn, with margin improving modestly to 6.3%. Life Science revenue grew 16.4% to ¥34.92bn and its operating loss narrowed to ¥3.32bn from ¥6.16bn, although profitability remains negative. Ceramics and Other returned to a ¥0.77bn operating profit from a near-break-even loss in the prior year. The five-factor DuPont interest burden was 0.909x, indicating that net finance costs reduced EBIT-to-pre-tax-profit conversion by approximately 9.1%, while the 0.653x tax burden further constrained final returns. Annualized ROE remains below the 8% benchmark despite the Q1 earnings rebound, so sustained margin gains and improved capital productivity remain necessary for a stronger return profile.

Growth Assessment

Top-line growth was broad-based, with every reported operating segment except Ceramics and Other posting higher external revenue. Chemicals recorded the largest absolute sales increase, up ¥13.91bn YoY, followed by Automotive at ¥8.89bn and Building Glass at ¥8.77bn. Building Glass' return to profitability is particularly important because it converted a prior-year loss into a positive contribution. Chemicals combined 9.7% revenue growth with 37.3% operating-profit growth, supporting the view that Q1 growth included meaningful earnings leverage. Automotive growth was more moderate but profit grew faster than sales, indicating improved mix or fixed-cost absorption. Electronics requires closer monitoring: revenue expanded, but segment operating income fell by ¥1.76bn, suggesting product mix, pricing, utilization, or cost pressure. Life Science's narrowing loss is a positive trajectory, but this segment still reduced consolidated segment earnings by ¥3.32bn. The FY2026 forecast calls for revenue of ¥2,200bn, operating income of ¥150bn and parent-attributable profit of ¥77bn. Q1 progress was 24.5% of sales guidance, 25.6% of operating-income guidance and 29.7% of parent-attributable-profit guidance, versus a 25% seasonal reference point. The maximum variance from the standard Q1 progress rate is 4.7 percentage points, below the 10-point threshold that would indicate a material deviation. The unchanged forecast therefore appears consistent with Q1 performance rather than signaling a management assumption of an accelerated full-year run rate. The low 2/10 growth consistency score nonetheless indicates that earnings have not followed a consistently smooth historical growth pattern, which is consistent with AGC's exposure to cyclical industrial end markets.

Financial Health

The balance sheet retains a solid equity base, with total equity of ¥1,719.47bn and an equity ratio of 49.9%. Total liabilities were ¥1,276.06bn, equivalent to 42.6% of total assets. The reported debt-to-equity ratio of 0.74x is within the conservative sub-1.0x benchmark and does not indicate excessive balance-sheet leverage. The current ratio was approximately 1.41x, calculated from ¥1,028.91bn of current assets and ¥729.87bn of current liabilities; this is above 1.0x and therefore does not indicate a near-term liquidity warning, although it is below the 1.5x healthy benchmark. Cash and trade receivables totaled ¥463.09bn, covering approximately 63.5% of current liabilities before inventory, so liquidity depends partly on inventory conversion and ongoing access to funding. Current interest-bearing debt, including short-term borrowings and current maturities of long-term borrowings, was ¥249.27bn. This amount is covered by cash of ¥119.85bn and current assets of ¥1,028.91bn, mitigating maturity-mismatch risk, although it increased in the quarter as short-term debt rose to ¥134.98bn. Non-current interest-bearing debt increased to ¥453.47bn. The financing structure supported the quarter's investment program and dividend payments, but it also leaves future interest expense sensitive to refinancing conditions. Finance costs of ¥4.27bn exceeded finance income of ¥3.42bn, producing a net finance cost of ¥0.85bn. Goodwill was ¥51.89bn, only 3.0% of equity and 1.7% of assets, while intangibles were 1.9% of assets; M&A-related asset concentration and goodwill impairment dependence are consequently limited. Net defined-benefit liabilities were ¥49.80bn and non-current provisions were ¥12.95bn, which should remain part of long-term liability monitoring.

Notable B/S Changes

Cash and cash equivalents: +¥251.76bn versus FY2025-end to ¥1,198.48bn - liquidity increased, supported by positive operating cash flow and net financing inflows. Trade receivables: +¥188.42bn versus FY2025-end to ¥3,432.38bn - a major use of operating cash that should be monitored for collection timing and demand quality. Short-term interest-bearing debt: +¥364.43bn versus FY2025-end to ¥1,349.81bn - short-term funding increased materially during a capex- and dividend-intensive quarter. Long-term interest-bearing debt: +¥239.54bn versus FY2025-end to ¥4,534.68bn - increased long-term funding supports investment liquidity but raises refinancing and interest-cost sensitivity. Non-controlling interests: -¥219.94bn versus FY2025-end to ¥2,246.01bn - the decline contributed to the ¥122.51bn reduction in total equity despite positive comprehensive income. Inventories: +¥69.79bn versus FY2025-end to ¥4,723.94bn - inventory remains 15.8% of assets and is consistent with the elevated 106-day DIO alert.

Cash Flow Quality

Cash conversion was strong at the earnings level: operating cash flow of ¥42.61bn was 1.87x consolidated net income of ¥25.15bn, comfortably above the 0.8x quality-warning threshold. The accruals ratio was negative 0.7%, also supportive of earnings backed by cash generation rather than aggressive accrual recognition. Depreciation and amortization of ¥48.14bn exceeded operating income of ¥38.47bn, underscoring the capital-intensive nature of AGC's manufacturing footprint and providing a substantial non-cash add-back to operating cash flow. Working-capital movements nevertheless absorbed cash during Q1. Trade receivables increased by ¥18.27bn, inventories increased by ¥6.07bn, and payables decreased by ¥8.35bn. These three movements collectively reduced operating cash flow by approximately ¥32.69bn and warrant attention given the seasonal and cyclical nature of the business. The quality alert on inventory days is material: DIO of 106 days is above both the 90-day warning threshold and the 60-day manufacturing benchmark. The root cause is that inventory represents a substantial ¥472.39bn, or 15.8% of total assets, tying up capital in a production-intensive operating model. For a glass, chemicals and electronics manufacturer, some inventory buffering is normal because production processes are continuous and supply chains can require raw-material and finished-goods availability; however, 106 days remains elevated and increases risks of weak demand absorption, price markdowns, obsolescence in electronics-related products, and future write-downs. The impact on the investment case is primarily weaker working-capital efficiency and reduced cash available for dividends, debt reduction and growth capex if inventory does not normalize. Capital expenditure was ¥62.71bn, or 11.7% of Q1 revenue, and exceeded operating cash flow. Consequently, free cash flow was negative ¥17.06bn. This negative quarterly FCF was financed alongside ¥22.30bn of parent dividends through a ¥39.74bn financing cash inflow, including increased short-term debt and net long-term debt issuance. The investment program may support capacity, replacement and technology needs, but its cash burden makes inventory normalization and disciplined capital allocation important.

Dividend Sustainability

The FY2026 dividend forecast is ¥210 per share, unchanged from the disclosed plan. Against forecast EPS of ¥363.12, the prospective dividend payout ratio is approximately 57.8%, within the sub-60% sustainability benchmark. The Q1 cash dividend payment of ¥22.30bn was almost equal to Q1 parent-attributable profit of ¥22.84bn, but quarterly cash payments should not be interpreted as a standalone payout ratio because the payment timing reflects the annual dividend schedule rather than Q1 earnings generation alone. Share repurchases were immaterial at ¥0.04bn, so the distinction between dividend payout ratio and total return ratio has no practical impact in this quarter. Operating cash flow of ¥42.61bn covered dividends paid, but did not cover both dividends and ¥62.71bn of capital expenditure. Free cash flow was therefore negative ¥17.06bn before dividends, implying that capital spending and shareholder distributions together relied on balance-sheet funding during Q1. The ¥1,719.47bn equity base and reported 0.74x debt-to-equity ratio provide capacity to absorb temporary cash-flow deficits. Sustainability over the full year depends on delivery of ¥77bn parent-attributable profit guidance, conversion of earnings to cash, and moderation of working-capital absorption, especially inventories. The unchanged dividend plan and forecast payout ratio indicate that the stated policy is supportable if full-year earnings guidance is achieved.

Risk Assessment

Business risks include High priority — Inventory and demand risk: annualized DIO of 106 days exceeds both 90-day and 60-day warning benchmarks. Elevated inventory may reflect slower demand absorption or inventory buffering across glass, chemicals and electronics, and can lead to working-capital drag, pricing pressure, or inventory write-downs., High priority — Electronics profitability risk: Electronics revenue increased 4.1% YoY, but operating income declined 12.6% and margin compressed by about 250bp to 13.7%. This exposes group earnings to display, semiconductor-related and optical-component cycle weakness., Medium priority — End-market cyclicality: Building Glass depends on construction activity, Automotive depends on vehicle production volumes and model mix, Chemicals is exposed to industrial demand and feedstock economics, and Life Science remains loss-making despite a narrower loss., Medium priority — Input-cost, energy and environmental-regulation risk: AGC's glass and chemical production base is energy- and process-intensive, leaving profitability sensitive to energy prices, raw-material availability, carbon costs and environmental compliance requirements., Medium priority — Currency and overseas operating risk: the global production and sales footprint creates exposure to exchange-rate movements, regional demand conditions and geopolitical or trade-policy disruption..

Financial risks include Medium priority — Free-cash-flow funding risk: Q1 free cash flow was negative ¥17.06bn because ¥62.71bn of capex exceeded ¥42.61bn of operating cash flow. Dividends and investment spending were supported by financing inflows., Medium priority — Refinancing and interest-cost risk: current interest-bearing debt was ¥249.27bn and non-current debt was ¥453.47bn. The current ratio of approximately 1.41x is adequate but below the 1.5x healthy benchmark, while higher debt funding can increase sensitivity to interest rates., Low priority — Pension and provision exposure: net defined-benefit liabilities of ¥49.80bn and non-current provisions of ¥12.95bn represent ongoing long-term funding and estimation considerations..

Key concerns include The central operational issue is whether the Q1 inventory build reverses without margin sacrifice; DIO of 106 days is the explicit quality alert and should be tracked against sales volumes, pricing and future operating cash flow., The Q1 earnings recovery is broad but uneven: Building Glass and Chemicals improved sharply, whereas Electronics experienced a material profit decline and Life Science remained loss-making., Annualized ROE of 5.3% remains below the 8% benchmark despite improved Q1 profit, indicating that the company still needs sustained margin improvement and stronger asset productivity., Q1 operating income already reached 25.6% of full-year guidance, while guidance was unchanged; subsequent quarters must demonstrate that this performance can withstand industrial-cycle and cost volatility..

Investment Implications

Key takeaways include Revenue grew 7.7% YoY and operating income grew 48.9% YoY, with operating margin expanding 198bp to 7.2%., Chemicals is the core profit contributor at ¥15.22bn of Q1 segment operating income, while Building Glass delivered the largest turnaround by returning to a ¥4.68bn profit., Electronics remains a high-margin business but its ¥1.76bn YoY operating-profit decline is a key offset to otherwise strong group momentum., Reported earnings are cash-backed, with OCF/Net Income of 1.87x and a negative 0.7% accruals ratio, but elevated inventories and capex caused negative free cash flow., The FY2026 forecast is unchanged, and Q1 achievement rates of 24.5% for revenue, 25.6% for operating income and 29.7% for owner earnings indicate broadly on-track execution..

Metrics to watch include Inventory days and absolute inventories, particularly whether DIO improves from 106 days, Electronics segment revenue, operating income and margin, Building Glass profitability following its turnaround from a prior-year loss, Chemicals margin resilience amid energy, feedstock and industrial-demand changes, Operating cash flow, capital expenditure and free-cash-flow recovery, Short-term and long-term interest-bearing debt, financing costs and current-ratio trend, Progress versus FY2026 operating-income guidance of ¥150bn and parent-attributable-profit guidance of ¥77bn.

Regarding relative positioning, AGC combines a diversified global glass, automotive, electronics, chemicals and life-science portfolio with a capital-intensive asset base. Its 49.9% equity ratio, 0.74x reported debt-to-equity ratio and low goodwill exposure support balance-sheet resilience relative to highly acquisitive industrial peers. However, annualized ROE of 5.3%, a 7.2% operating margin and DIO of 106 days indicate that capital efficiency and working-capital discipline remain the principal areas requiring improvement.